Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Frontiers in Medicine

article

Thomas Mika¹  Roland Schroers¹  Katharina Strate¹  Swetlana Ladigan¹  Clemens Aigner²  Uwe Schlegel³  Iris Tischoff⁴  Sabine Tischer-Zimmermann⁵  Britta Eiz-Vesper⁵  Britta Maecker-Kolhoff⁶ 

[1] Department of Medicine, Ruhr-University Bochum;Department of Thoracic Surgery, University Hospital Essen;Department of Neurology, Ruhr-University Bochum;Department of Pathology, Ruhr-University Bochum;Institute for Transfusion Medicine, Hannover Medical School;Department of Pediatric Hematology and Oncology, Hannover Medical School

关键词: PTLD;    alloHSCT;    aggressive lymphoma;    brentuximab vedotin (BV);    third-party EBV-specific T-lymphocytes;   

DOI  :  10.3389/fmed.2019.00295

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.

【 授权许可】

CC BY